From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2016 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从需要说服的候选者转变为已批准、指定、列入、合格、注册、报销或预先授权的选择,进入买家自身的采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得公司未来业务的相当一部分可以在没有每次订单的单独销售事件的情况下到达,并且管理层是否传达了这种准入状态是新的,以至于它所带来的大部分交易量仍在前方,尚未反映在报告的结果中。 在电话会议中,管理层讨论了ProTmune的临床进展,包括FDA的快速通道和孤儿药指定,以及欧洲药品管理局的孤儿药指定。他们提到修改了临床试验方案,以盲法进行,并认为这有可能支持加速注册。然而,这并不涉及将公司纳入买方的采购或报销系统。他们讨论的是监管指定和临床试验设计,而不是市场准入或报销状态。 关于FATE-NK100,他们提到已提交IND,并计划在明年初开始临床试验。这也不是关于市场准入。 关于ToleraCyte,他们提到与FDA进行了积极的pre-IND会议,并计划进行临床试验。同样,这不是关于报销或处方集。 关于iPSC平台,他们提到计划向FDA提交临床前简报包,以获取指导。这也不是关于市场准入。 整个电话会议中没有提到公司已被列入任何处方集、报销目录、供应商名单或类似系统。管理层没有描述公司已从需要说服的候选者转变为默认选择。他们谈论的是临床开发和监管进展,而不是商业市场准入。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.